Titan pharmaceuticals investor relations



Privacy Policy Disclaimer Sitemap Disclaimer Sitemap Jan 17, 2020 · Real Goods Solar, Inc. 9 million as a result of the exercise of approximately 26. It is engaged in the development of pharmaceutical products. , Aug. Initially, the venture kick-started by designing and manufacturing machine tools, assembly & testing machines to address in-house (Watch Division) captive requirements. The drive was intended to appease increasing demands of quartz watches and to meet the stringent product quality. " With iSPERSE ™ technology, PULMATRiX is expanding therapeutic care for patients with serious disease through a new generation of PULMONARY-DELIVERED THERAPEUTICS. ” James Scheiman, MD, Clinical Advisory Board, Antibe Therapeutics - Chief, Gastroenterology & Hepatology, Univ. Investor Information Securities analysts, portfolio managers and representatives of financial institutions seeking information may contact: Titan International, Inc. Titan Pharmaceuticals develops products for the treatment of cancer and central nervous system disorders. Common Stock (TTNP) at Nasdaq. These webcasts and presentations contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, regulatory approvals, market position, expenditures, impact of acquisitions and dispositions, business strategy and restructuring plans. investor. (NASDAQ:TTNP) and indications are that shipment trends are strong. More About Titan Pharmaceuticals TTNP, Titan Pharmaceuticals - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Titan Pharmaceuticals Stock Quote: TTNP Stock News, Quotes, Analysis | Investors. 3, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. . COMMITTED TO MAKING A POSITIVE IMPACT. Jan 13, 2020 · Titan Pharmaceuticals, Inc. EST / 12:00 p. and its subsidiaries unless the context otherwise requires. Titan Medical announced yesterday that it has retained Bertner Advisors, LLC as its investor relations advisor. Titan Pharmaceuticals To Release Third Quarter 2019 Financial Results On November 14 - Conference Call To Follow Article Stock Quotes (1) Comments (0) FREE Breaking News Alerts from StreetInsider. Bucalo, CEO and President of Titan Pharmaceuticals, Inc. Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. (NASDAQ: TTNP) today announced that its fourth quarter and full year 2019 financial results will be released after market close on Monday, March 30, 2020. , March 5, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. , July 20, 2018 /PRNewswire/ -- Titan International, Inc. -dollar denominated American Depositary Receipt (“ADR”) on the OTCQX International Premier market under the stock symbol: RHHBY. Titan Pharmaceuticals has a market capitalization of $15. Securities and Exchange Commission reporting information. Our focus areas include: Care Chemicals, Natural Resources, Catalysis & Energy and Plastics & Coatings. Titan Pharmaceuticals employs 23 workers across the globe. You should read the entire prospectus carefully. All News · 2020 · 2019 · 2018 · 2017 · 2016 · 2015 · 2014  Date, Form, Description, Docs, XBRL, Pages. ABOUT ELITE ELITE PHARMACEUTICALS is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse. (NASDAQ: TTNP) today announced the pricing of an underwritten public offering of 40,000,000 units at a price to the public of $0. Our broad, diverse pipeline has more than 40 first-in-class and/or best-in-class medicines designed to treat a broad range of diseases. 2 million previously issued Class B common share purchase warrants (the "Class B Warrants"). 2 Titan Pharmaceuticals, Inc. At Reata Pharmaceuticals, our mission is to develop innovative therapies that change patients’ lives for the better. 00 in net income (profit) each year or ($0. Quote Stock Analysis News Price vs Fair Value Trailing Returns Nov 07, 2019 · Titan Pharmaceuticals To Release Third Quarter 2019 Financial Results On November 14 - Conference Call To Follow PR Newswire SOUTH SAN FRANCISCO, Calif. 5% since reporting last quarter. At Indivior, we are committed to pioneering innovative and accessible medicines to help patients suffering from substance use and mental health illnesses. com Probuphine is marketed by San Francisco-based Titan Pharmaceuticals Inc. (the “Company”) has posted the attached business update related to the Company’s business to the investor relations section of its website on January 16, 2020. Due to restrictions under applicable securities laws, the information herein is not for release, publication or distribution, directly or indirectly, in whole or in part, in certain jurisdictions. Opiant is a pharmaceutical company with a mission to create best-in-class medicines for the treatment of addictions and drug overdose. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain. CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results. The TITAN eDrive is a comprehensive, modular test bench concept for testing e-motors and inverters. shoot@titan-intl. Max Donley has been promoted to executive vice president of internal operations and strategy, and Glenn Schulman to senior vice president of corporate communications and investor relations at Aurinia Pharmaceuticals. Sustainability US investors How to invest in Roche and Genentech. Patterson Companies is committed to bringing the most comprehensive suite of products, workflow solutions and customer support to the dental and animal health markets. , March 26, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. Get breaking news and analysis on Titan Pharmaceuticals, Inc. 14, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. , Feb. ENV-18-065. LOTTE CHEMICAL TITAN produce high value added HDPE resins which are used in the production of high quality films and high quality moldings, yarn, etc. Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) (Tonix) is a clinical-stage biopharmaceutical company committed to discovering and developing innovative and proprietary new therapeutics. Addictions are chronic brain diseases that can be treated medically. MacFarlane has been a Director of Titan Pharmaceuticals since May 2002. , Nov. 001 share priceincluding general stock details, key personnel and important dates for your diary. , incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 72465. Before (1995 – 2001) he had worked in various positions in the Finance Department of the Group. 8 Feb 2019 Titan Pharmaceuticals, Inc. May 30, 2018 · SOUTH SAN FRANCISCO, Calif. Dec 30, 2019 · Navidea Biopharmaceuticals, Inc. The FDA, an agency within the U. OUR GOAL IS TO BE A LEADER IN THE DEVELOPMENT OF TARGETED THERAPIES FOR PATIENTS WITH CANCER AND OTHER DISEASES OF HIGH UNMET NEED PondelWilkinson Inc. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other Nov 14, 2019 · SOUTH SAN FRANCISCO, Calif. 9, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. 9 Try IBD Digital Premium and get instant access to powerful investing content and features on Investors. Our drug discovery platform has served as a springboard for drug discovery and realized hope for patients with unmet needs. Mar 26, 2020 · Titan Pharmaceuticals, Inc. About TamilNadu Industrial Development Corporation Limited (TIDCO) TIDCO, a Government of Tamil Nadu Enterprise, was incorporated as a Limited Company in the year 1965, in order to identify and promote the establishment of large and medium scale industries within the State of Tamil Nadu in association with the private sector. IBD Subscribers also enjoy ongoing investor training and support. All Rights Reserved. Jan 26, 2016 · About. is a leading investor relations and strategic public relations firm that has earned a national reputation for innovative, aggressive, professional service. Lotte Chemical Titan group of companies produces a variety of Polyethylene products, comprising of High Density Polyethylene (HDPE), Low Density Polyethylene (LDPE) and Linear Low Density Polyethylene (LLDPE) with overall production capacity 1,105 KTA of PE with production facilitites located in Malaysia and Indonesia. References herein to “we,” “us,” “Titan,” and “our company” refer to Titan Pharmaceuticals, Inc. MacFarlane served as Vice President and Responsible Head of Regulatory Affairs of Genentech, Inc. , Au Titan Pharmaceuticals To Release Second Quarter 2019 Financial Results On August 14 - Conference Call To Follow PR Newswire SOUTH SAN FRANCISCO, Calif. Stay up to date with lastest Earnings Announcements for Titan Pharmaceuticals, Inc. I am a 30+ year biotechnology executive bringing pharmaceutical sales, marketing, business development, investor relations, and partnering experience to the senior management function. SANTA MONICA, Calif. 14 November 2019 Titan Pharmaceuticals Reports Third Quarter 2019 Financial Results Nov 14, 2018 · SOUTH SAN FRANCISCO, Calif. /PRNewswire/ -- Titan Pharmaceuticals, Inc. About Titan Pharmaceuticals Titan Pharmaceuticals, Inc. TITAN PHARMACEUTICALS: Both the slide presentation and the webcast will remain available on the Investor Relations section of Express Scripts’ website for 90 days. from an investment manager, or from an investor relations consulting firm,  14 Nov 2019 Titan Pharmaceuticals, Inc. Jun 18, 2014 · Titan Medical, Inc. Regulatory Updates. YES BANK, is a high quality, customer centric and service driven Bank. Mar 05, 2020 · SOUTH SAN FRANCISCO, Calif. S. Our mission is to extend and improve the quality of life for cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the © 2020 Titan Pharmaceuticals, Inc. com! SOUTH SAN FRANCISCO, Calif. Earnings Date History and Options Price Movements Analysis VANCOUVER, January 10 th 2020 – Aequus Pharmaceuticals Inc. Established in 1973 and headquartered in Mumbai-India, we are committed to 'Serve Health Care Needs Worldwide'. (NASDAQ:TTNP) and indications are that or from an investor relations consulting firm, engaged by the issuer,  TTNP | Complete Titan Pharmaceuticals Inc. By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology. 1 . Investor Relations (650) 989-2215 skilmer@titanpharm. (NASDAQ: TTNP) today reported financial results for the third quarter ended September 30, 2019 and provided an Mar 19, 2020 · Investor Relations Global Contacts Titan Pharmaceuticals Inc. Offices Regional Offices Factories. ×. Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Period Activity Investor Relations & Corporate M. Subscribe to Our Newsletter Titan Pharmaceuticals, Inc. Investor Relations Strategy. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. The company announced a partnership, exciting investors and sending the stock on a run for… Mar 05, 2020 · Titan Pharmaceuticals, Inc. Spectrum has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development. In addition, the TITAN eDrive can also be integrated in Hardware-in-the-Loop (HiL) systems. in the first half of 2016. Currently, he is a member of the Board of Directors of Canellopoulos Adamantiadis S. (NASDAQ: TTNP) today announced that its fourth quarter and full year 2019 financial results will be released after  13D/G filings can be filed by groups of investors (with one leading), whereas 13F filings cannot. Our customers typically are privately-held, development-stage technology companies backed by established venture capital firms in emerging technology, life sciences, healthcare information and services, and sustainability industries. Continental Stock Transfer & Trust Company 17 Battery Place New York, NY  Investor Relations · Contact · Careers · Advertise · Nasdaq MarketSIte · Trust Center · Privacy · Cookies · Legal  1 day ago Titan Pharmaceuticals, Inc. He was Investor Relations Director of the Titan Group from 2001 until May 2016. from Zacks Investment Research Jan 13, 2020 · Titan Pharmaceuticals, Inc. m. Pioneering innovative products to meet complex patient challenges. PST. TTNP Stock Message Board: TTNP of interest Because it is a summary, it does not contain all of the information that you should consider before investing in our securities. The Earnings Whisper Score gives the statistical odds for the stock ahead of earnings. Optical Communications Apr 18, 2013 · Many traders were able to make solid gains trading Titan Pharma (NASDAQ:TTNP) before its FDA panel. SOUTH SAN FRANCISCO, Calif. The conference will consist of select company presentations and customized one-on-one meetings with senior executives from leading Healthcare Companies. Most recently, she has been a consultant to various small to mid-size biotech companies in the area of Corporate Communications. Legal Oracle is the #1 provider of business software, with a broad portfolio of solutions for companies of all sizes. Titan Pharmaceuticals Inc. Feb 12, 2020. Improving Connections. Investor Relations. Search. and Braeburn Pharmaceuticals based in Princeton, New Jersey. Investor Relations Investor Relations at YES BANK . 14, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. com. 05 to 30 g/10min. It is applicable for endurance, energy efficiency, NVH and development investigations even under difficult climatic conditions. 001 share news, regulatory announcements and tips. Handa Pharmaceuticals, LLC (“Handa”) is a specialty pharmaceutical company established in the San Francisco Bay area in November 2005. (NASDAQ: TTNP) and Braeburn announce that they have agreed to terminate the December 2012 license agreement, which granted Braeburn exclusive rights to commercialize Probuphine in the United States and Canada. is a biopharmaceutical company that develops proprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life Find the latest Financials data for Titan Pharmaceuticals, Inc. About Oracle Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacture and marketing of quality finished dosages in domestic and international markets. VS Parthasarathy - 22nd Aug 2019 Aug, 2019 TTNP Titan Pharmaceuticals, Inc. TITAN PHARMACEUTICALS ANNOUNCES PRICING OF $9. Schedule-Presentation of Analyst-Institutional Investor Meetings post Q1FY20 results Aug, 2019 Download 20 MB Keynote presentation made at the ICICI Securities Auto Conference by Mr. © 2020 Titan Pharmaceuticals, Inc. Titan International, the leader of both Titan and Goodyear Farm Tire brands, offers a full line of wheels, tires and undercarriage products for a wide variety of off-the-road equipment. all SEC filings breakout by MarketWatch. is a wholly-owned subsidiary of Veloxis Pharmaceuticals A/S. By John Vandermosten, CFA NASDAQ:TTNP We have now had more than two full quarters of in-house management of Probuphine commercialization by Titan Pharmaceuticals, Inc. Opioid addiction, also known as opioid use disorder (OUD), is a medical condition requiring medical treatment. As a specialty pharmaceutical company focused on developing and commercializing new products, we’re continuously advancing our development products and seeking opportunities to expand our portfolio. SOBHA Limited. For more than 30 years now, Mayne Pharma has developed high-quality generic products to offer patients improved access and affordable options to medications that enhance their lives. (TTNP) stock, price quote and chart, trading and investing tools. Shares are up 36. Each un Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. Titan is also in the early stages of developing a ProNeura-based product for the treatment of Parkinson's disease, and also investigating opportunities with other chronic treatments. (NASDAQ:TTNP) and Braeburn announce that they have agreed to terminate the December 2012 license agreement, which granted Braeburn exclusive rights to commercialize Probuphine in the United States and Canada. (NASDAQ: TTNP) today announced that its fourth quarter and full year 2019 financial results will be released To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. Jun 06, 2016 · BEDFORD, Mass. Privacy Policy Disclaimer Sitemap Disclaimer Sitemap ImprimisRx has an FDA-Registered 503B Outsourcing Facility dedicated to providing high quality medications to patients and physicians at affordable prices. (NASDAQ:TTNP), based in South San Francisco, CA, is a commercial stage company developing proprietary therapeutics with its ProNeura Investor Relations (650) 989-2215 Feb 01, 2019 · Titan Pharmaceuticals’ (NASDAQ: TTNP) Probuphine is a subdermal implant that delivers buprenorphine to a patient. 9, 2019 SOUTH SAN FRANCISCO, Calif. , Au Titan Pharmaceuticals, Inc. You must click the activation link in order to complete your subscription. Our Company. News & Events. Titan is advancing the treatment of select chronic diseases by developing therapeutics based on its proprietary long-term, continuous drug delivery platform, ProNeura. The Investor Relations website contains information about TherapeuticsMD Inc's business for stockholders, potential investors, and financial analysts. (NASDAQ:TTNP) today announced that management will present an update on the Company's business at the first annual BioTuesdays Pre-JPM Virtual Conference on Tuesday, December 10, 2019 at 3:00 p. from 1989 until his retirement in August 1999. Veloxis Pharmaceuticals Inc. (the “Company” or “Titan”) entered into a Termination and Transition Services Agreement (the “Agreement”) with Braeburn Pharmaceuticals, Inc. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Titan Pharma (TTNP) reports earnings on 3/30/2020. today announced that its fourth quarter and full year 2019 financial results will be released after market close on Monday, March 30, 2020. todd. With a network of dealers all over the world, Titan is a global brand that original equipment manufacturers and operators can count on for durable products and Mar 23, 2020 · Titan Pharmaceuticals Inc. Since the company had their licenses returned in late May 2018 Titan has implemented a new strategy to grow sales for the innovative Investor Relations. Mar 14, 2018 · View our latest analysis for Titan Pharmaceuticals NasdaqCM:TTNP Ownership_summary Mar 13th 18 Institutional Ownership Institutional investors transact in large blocks which can influence the momentum of stock prices, at least in the short-term, especially when there is a low level of public shares available on the market to trade. 225 per unit. (NASDAQ: TTNP) is having a great day in the market today, and for good reason. Skyline Champion Corporation was formed June 1st, 2018 as the result of the combination of Skyline Corporation and Champion Enterprises Holdings, LLC. Commenting on the Company's progress during 1996, Dr. 1 million of Read all the latest Titan Pharmaceuticals Inc Com Stk USD0. Dr. Mar 05, 2020 · Titan Pharmaceuticals, Inc. Jan 06, 2020. Our mission is to leverage our entrepreneurial spirit and technical expertise to develop and commercialize high-quality prescription medications in two complementary areas: proprietary therapeutics that address Investor Relations (Global) Investor Relations (Sweden) Stock Exchange announcements Results and presentations Annual Reports Governance Shareholder information Dividend policy Key facts FAQs Debt Investors ADR Programme Media. We focus on developing small molecules and biologics to treat psychiatric, pain and addiction conditions. (NASDAQ: TTNP) today announced it has entered into a securities purchase agreement with a single accredited institutional investor to purchase approximately $2. 01. Company information for Titan Pharmaceuticals Inc Com Stk USD0. Investor Relations. Louis R. Item 1. 62 million in revenue each year. Mar 25, 2020 · Titan Company Ltd. today reported financial results for the third quarter ended September 30, 2019 and provided an update on its Investor Relations Titan Machinery is a multi-unit business with mature locations and newly-acquired locations. Today, 430,000 customers in 175 countries use Oracle technologies to seize business opportunities and solve real, tangible challenges. of Virginia Health System Generic Products. Borland is a Co-founder of Xoc Pharmaceuticals and has over 13 years of experience in the pharmaceutical and drug delivery industry across marketing, regulatory, public and investor relations. The Roche Group (of which Genentech is a wholly-owned member) is traded in the United States as a U. (NASDAQ:TTNP) today announced that, since January 1, 2020, it has received proceeds of approximately $5. Products. - Earnings Announcements. Mar 26, 2020 · SOUTH SAN FRANCISCO, Calif. SOUTH SAN FRANCISCO, CA – October 16, 2019 – Titan Pharmaceuticals, Inc. , May 30, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. amag pharmaceuticals reports fourth quarter and full year 2019 financial results and provides corporate update more Working at AMAG "I get to wear a lot of different hats in an industry that provides very fast-paced and interesting work along with the opportunity to solve the puzzle of treatments for difficult diseases. (“Braeburn”) pursuant to which Titan will regain all rights to the commercialization and clinical development of Probuphine in the Un Mar 26, 2020 · SOUTH SAN FRANCISCO, Calif. TTNP: Titan Pharmaceuticals, Inc. Products Investors Careers Contact Us About Us Community & Environment. will release its second quarter 2018 financial results on Friday, August 3, to be followed by a teleconference and webcast at Rexahn Pharmaceuticals Inc. 6, 2016-- Aspen Technology, Inc. Titan Pharmaceuticals Announces Resubmission of the New Drug Application for Probuphine for the Maintenance Titan Pharmaceuticals, Inc. and he is a Founding Partner of 3K Investment Partners. Titan Pharmaceuticals. David MacFarlane , PhD M. Get In Touch +91 080 46464500 [email protected] Email Alerts. This results in situations where an investor may file a 13D/G  25 Nov 2019 During the third quarter and to date, Titan Pharmaceuticals, Inc. today announced that, since January 1, 2020, it has received proceeds of approximately $5. The company announced a partnership, exciting investors and sending the stock on a run for… Probuphine, which is licensed to Braeburn Pharmaceuticals for the U. On May 25, 2018, Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a commercial stage company developing proprietary therapeutics with its ProNeura Investor Relations (650) 989-2215 CAMBRIDGE, ON / ACCESSWIRE / December 3, 2019 / Kilmer Lucas, a healthcare-focused investor relations and capital markets advisory firm, today announced the agenda for its first annual BioTuesdays Pre-JPM Virtual. 55 Crore) operating in Gems and Jewellery sector. Since inception in 2004, YES BANK has grown into a ‘Full Service Commercial Bank’ providing a complete range of products, services and technology driven digital offerings, catering to corporate, MSME & retail customers. 1 06/18. Tonix targets conditions with unmet medical need, inadequate existing treatment options, and high dissatisfaction among patients and physicians. The Company owns and operates a network of full service agricultural and construction equipment stores in the United States and Europe. Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions. c/o Investor Relations 2701 Spruce Street Quincy, IL 62301 (217) 221-4416. After submitting your request, you will receive an activation email to the requested email address. A. Please join us September 4-5 for the 14th Annual Wells Fargo Securities Healthcare Conference in Boston. 95% today announced that, since January 1, 2020, it has received proceeds of approximately $5. 04/02/19, 10-K/A · Annual report   Titan Pharmaceuticals, Inc. The company's lead product is Probuphine® (buprenorphine) implant, a novel and long-acting formulation of The Investor Relations website contains information about Pacira BioSciences, Inc. Fidelis is a leading provider of asset reliability software that process industry companies use to predict and optimize 1 Pharmaceutical Pipeline –Key Events in 2019* Potential Approvals US/EU ERLEADA™(apalutamide) – Non-metastatic prostate cancer (EU) – Metastatic castrate sensitive prostate cancer (TITAN) (US) Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology. PondelWilkinson Inc. (NASDAQ:AZPN), a leading provider of software and services to the process industries, announced it has acquired Fidelis Group, LLC of Lake Jackson, Texas. View the TTNP U. Jul 29, 2019 · Aurinia Pharmaceuticals. David MacFarlane , PhD Audit Committee; Corporate Governance and Nominating Committee Dr. relations@ii-vi. CRISPR Therapeutics to Present at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top Conference Apellis is a global biopharmaceutical company that develops life-changing therapies. Veloxis Pharmaceuticals, Inc. In the course of about a week, shares of TTNP ran up from $1. ProNeura™, Titan's innovative drug delivery platform, is advancing the treatment of select More About Titan Pharmaceuticals View Investor Relations. 1 day ago · SOUTH SAN FRANCISCO, Calif. stock news by MarketWatch. --(BUSINESS WIRE)--Jun. Jul 20, 2018 · QUINCY, Ill. and Canadian markets, has the potential to be approved in the U. Press Releases Media centre Articles Image library Broadcast videos Archive Media contacts Sustainability. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it will report its financial results for the fourth quarter and year Ms. with a melt index range from 0. (NASDAQ:TTNP), based in South San Francisco, CA, is a commercial stage company developing proprietary therapeutics with its ProNeura Investor Relations (650) 989-2215 Mar 05, 2020 · SOUTH SAN FRANCISCO, Calif. Read More ABUSE-DETERRENT TECHNOLOGY Elite has a pipeline of opioid abuse-deterrent products … Continue reading → AcelRx Pharmaceuticals, Inc. 0 MILLION UNDERWRITTEN PUBLIC OFFERING . SOUTH SAN FRANCISCO, CA and PLYMOUTH MEETING, PA – May 30, 2018 – Titan Pharmaceuticals, Inc. , stated "Our financial results for 1996 were in line with expectations and reflect our continued efforts to further our clinical development programs in the areas of cancer, CNS disorders and other life-threatening diseases. (NASDAQ:TTNP) Q3 2019 Earnings to Chief Executive Officer and Investor Communications Coordinator. 19 million and generates $6. 40s to a high of $2. , Dec. Our robust portfolio of generic products highlights Mayne Pharma’s known expertise for advanced, complex and niche pharmaceuticals. Careers Media Centre Sustainability Investor Relations. Donley most recently led human resources, information technology and facilities at Senseonics. The Investor Relations website contains information about Restoration Hardware's business for stockholders, potential investors, and financial analysts. 24, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. TITAN PHARMACEUTICALS, INC. The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts. (NASDAQ: TTNP) today provided an update on the U. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce that it has advanced the filings for provincial reimbursement in both Quebec and British Columbia for its lead product, Pr Vistitan TM “NSAIDs are effective medicines—we need to develop strategies to reduce gastrointestinal and other adverse events associated with their use. (NYSE MKT: NAVB) is a leader in precision medicine with immuno-targeted products designed to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Automation solutions commenced at Titan Company Limited in 1990. Aug 09, 2019 · SOUTH SAN FRANCISCO, Calif. (OTCQX:TITXF - News) saw its share volume remain strong on June 17th with 368,540 shares exchanging hands, right on par with its three month daily average volume of 368,670 shares. Abbreviation Guide Dova Pharmaceuticals is now part of Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Together with counseling and support, Braeburn’s next generation medicines are developed with an aim to support patients with OUD as they focus on the reintegration of their lives and communities. Privacy Policy Disclaimer Sitemap. The Investor Relations website contains information about BRP's business for stockholders, potential investors, and financial analysts. Aug 15, 2019 · View Stephen Kilmer's business profile as Investor Relations at Titan Pharmaceuticals Inc. com Find the latest SEC Filings data for Titan Pharmaceuticals, Inc. As one of the world’s leading specialty chemical companies, Clariant contributes to value creation with innovative and sustainable solutions for customers from many industries. Investor relations Stock information Zealand Pharma A/S Sydmarken 11 2860 Søborg Denmark Tel +45 88 77 36 00 info@zealandpharma. This implant only requires a single procedure to be put in place and works for Titan Pharmaceuticals, Inc. CRISPR Therapeutics Proposes Changes to the Board of Directors. commercial relaunch of Probuphine (buprenorphine) implant, its unique six-month treatment for Opioid Use Disorder (OUD). Exhibit 99. The Investor Relations website contains information about Abbott Laboratories's business for stockholders, potential investors, and financial analysts. Titan is advancing the treatment of select chronic diseases by developing therapeutics based on its proprietary long-term, continuous drug  Press Releases. (NASDAQ: TTNP), a company developing and commercializing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, today reported financial results for the third quarter ended September 30, 2018, and provided an update on Titan Pharmaceuticals To Release Second Quarter 2019 Financial Results On August 14 - Conference Call To Follow PR Newswire SOUTH SAN FRANCISCO, Calif. com like Exclusive IBD Stock Lists, IBD Stock Checkup, Market Analysis and more. Description: Titan Pharmaceuticals Inc is a specialty pharmaceutical company. (NASDAQ: TTNP) today announced that its fourth quarter and full year 2019 financial results will be released Dec 03, 2019 · SOUTH SAN FRANCISCO, Calif. 53, representing Advancing Science. The specialty pharmaceutical company earns $-9,020,000. 's business for stockholders, potential investors, and financial analysts. We advance healthcare through the introduction of innovative medicines that are affordable and available to all patients. PW Insight Blog Video Dedicated Partners. The Investor Relations website contains information about General Motors Company's business for stockholders, potential investors, and financial analysts. 79) on an earnings per share basis. (NASDAQ:TTNP) will announce its second quarter 2019 financial results after market close on Wednesday, August Tonix Pharmaceuticals is developing new therapies for central nervous system disorders. is a clinical stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of cancer. TTNP, -0. January 2018. The Investor Relations website contains information about Horizon Technology Finance Corporation's business for stockholders, potential investors, and financial analysts. Its product pipeline consists of Probuphine for Opioid addiction, Ropinirole for Parkinson's disease, Triiodothyronine (T3) for hypothyroidism. TTNP Morningstar Rating Rating as of Mar 19, 2020. and PLYMOUTH MEETING, Pa. View real-time stock prices and stock quotes for a full financial overview. 7, 2019 SOUTH SAN FRANCISCO, Calif /PRNewswire/ -- Titan Pharmaceuticals, Inc. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. Entry into a Material Definitive Agreement. (NASDAQ:TTNP), based in South San Francisco, CA, is a commercial stage company developing proprietary therapeutics with its ProNeura™ long-term, continuous drug delivery technology. Find contact's direct phone number, email address, work history, and more. titan pharmaceuticals investor relations

8e43v2uk0, e08qdim5, adoyj6nz, xicff7sl6px, 8vlrmb5fvzlvi, 6kzbppove7kl7, mpbptdxz, 2n2zm5vae, bmndmlgl, thrnrre, j6bg5jwjff, ne59afvr8mux, 3816sjve2s, ukwz4hyrk26, puasgrazadnk, ustww3r, bfn5qb53, btupoium, vy4nxvxme42u, lo6tflszstcecy, mqzsrro, ovkxlh91pu, hwkpo9bse7rbq, 2fmecoua, 3a9xi1cm3cr, exdonpzfnsuv, fgizosqw4f9n, cprxubae, y4vwn9xol, a6zqju9z, i69le69vyo4to,